Premium
Cytogenetic aspects of the Canadian early and mid‐trimester amniotic fluid trial (CEMAT)
Author(s) -
Winsor Elizabeth J. T.,
Tomkins Darrell J.,
Kalousek Dagmar,
Farrell Sandra,
Wyatt Philip,
Fan YaoShan,
Carter Ronald,
Wang Hungshu,
Dallaire Louis,
Eydoux Patrice,
Welch J. Philip,
Dawson Angelika,
Lin Jim C. C.,
Singer Joel,
Johnson JoAnn,
Wilson R. Douglas
Publication year - 1999
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/(sici)1097-0223(199907)19:7<620::aid-pd599>3.0.co;2-e
Subject(s) - amniocentesis , amniotic fluid , medicine , gestation , obstetrics , randomized controlled trial , gynecology , bloody , pregnancy , fetus , prenatal diagnosis , surgery , biology , genetics
Cytogenetic results from a large multicentre randomized controlled study of 2108 amniotic fluids obtained at 11+0–12+6 weeks (EA) and 1999 fluids at 15+0–16+6 weeks (MA) were compared. There was no statistically significant difference in the rate of chromosome abnormalities (EA =1.9 per cent; MA=1.7 per cent) or level III mosaicism (EA=0.2 per cent; MA= 0.2 per cent) between the groups. Level I and Level II mosaicism occurred more frequently in MA. Maternal cell contamination was not significantly different between the groups, but maternal cells only were analysed from one bloody EA fluid. The number of repeat amniocenteses because of cytogenetic problems was 2.2 per cent in the EA group compared with only 0.3 per cent in the MA group. On average, culture of EA fluids required one day more than MA fluids. Although both culture success (97.7 per cent) and accuracy (99.8 per cent) were high for patients randomized to the EA group, routine amniocentesis prior to 13 weeks’ gestation is not recommended for clinical reasons including an increased risk of fetal loss and talipes equinovarus. Copyright © 1999 John Wiley & Sons, Ltd.